





Delivery of ROS Generating Anthraquinones Using Reduction-responsive 
Peptide-based Nanoparticles 
Pascal U. Richard,a Ioana Craciun,a Jens Gaitzsch,a Lev Weiner,b Cornelia G. Palivan*,a 
 
a Department of Chemistry, University of Basel, Mattenstrasse 24a, CH-4058 Basel, Switzerland, E-mail: cornelia.palivan@unibas.ch (C.P) 
b Weizmann Institute of Science, Rehovot 76100, Israel 
 
 
In order to limit the side effects associated with antitumor drugs such as doxorubicin, nanosized drug-delivery systems capable of selectively 
delivering and releasing the drug in the diseased tissue are required. We describe nanoparticles (NPs), self-assembled from a reduction 
responsive amphiphilic peptide, capable of entrapping high amounts of a redox active anticancer drug candidate and releasing it in presence of 
a reducing agent. This system shows a high entrapment efficiency with up to 15 mg drug per gram of peptide (5.8 mol%). Treatment of the NPs 
with reducing agent results in the disassembly of the NPs and release of the drug molecules. A reduction in cell viability is observed at drug 
concentrations above 250 nM in HEK293T and HeLa cell lines. This drug delivery system has potential for targeting tumor sites via the EPR 
effect while taking advantage of the increased reduction potential in tumor microenvironment. 
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               Introduction 
 
While cancer cases keep increasing, the major pharmaceutical 
treatments for tumors rely on chemotherapy, which results in 
numerous side effects. One of the major chemotherapeutic 
compounds is the anthracycline doxorubicin (DOX) which is known for 
its beneficial therapeutic effects on multiple forms of cancer, but also 
causes serious side effects, notably significant cardiotoxicity.[1, 2] One 
approach to reduce such side effects is through the use of nanosized 
drug delivery systems (DDS). Classic DDS are either composed of 
inorganic materials or made from self-assembled soft matter.[3-5] The 
latter are typically composed of amphiphilic molecules that can be 
loaded with various molecules of therapeutic interest.[6-9] The use of 
nanosized DDS allows for increased circulation times and 
nanoparticles of sizes up to 200 nm are known to accumulate in tumor 
tissue through the enhanced permeability and retention (EPR) effect,[6, 
10] thus allowing passive targeting of tumor sites. Already used 
clinically, liposomal formulations of DOX have been shown to 
moderately reduce the cardiotoxic side effects associated with 
administering the free drug.[1, 2, 6] 
Numerous biocompatible amphiphiles (e.g. lipids, diblock and triblock 
copolymers, peptides) have been shown to form nanoparticles (NPs) 
of different morphologies, such as micelles, vesicles and other 
complex structures.[7-9, 11] These nanostructures differ in size and 
ability to be loaded with various compounds. Structures containing a 
large aqueous lumen such as vesicles, for example, are favored for 
the delivery of hydrophilic drugs, whereas micelles are usually more 
suited for the delivery of hydrophobic drugs.[6-9] More complex self- 
assembly structures, namely multi-compartment-micelles (MCMs) can 
host both hydrophilic and hydrophobic drugs, making them especially 
versatile candidates for drug delivery. We have recently reported the 
redox-responsive amphiphilic peptide H3SSgT (of the sequence H2N- 
H3-X-[W-DL]3-W-CONH2, where X=–(CH2)2-S-S-(CH2)2-NH-CO-(CH2)2-CO– 
and DL = D-Leucine (Figure 1), that forms such MCMs. [12- 14] They were 
shown to efficiently entrap the model compound boron- 
dipyrromethene (Bodipy) and release it in presence of physiological 
amounts of reducing agent.[13] The MCMs are about 150 nm in 
diameter, making them suitable to deploy the EPR effect for tumor 
tissue uptake. In addition to a leaky vasculature leading to the EPR 
effect, the environment surrounding tumor tissues possess abnormal 
physico-chemical properties such as decreased pH, increased 
temperature and unusual redox potentials.[15-17] Due to the redox- 
responsive nature of the peptide used to form the MCMs, the system 
also has a built-in stimuli responsive delivery mechanism.[16, 18-20] We 
now aim towards taking this system a step further and apply it for a 
drug rather than model compounds. 
With respect to the target drug molecule, we focused on current 
research aimed at developing compounds with higher potency than 
DOX. One example of such a class of compounds are the 
anthraquinones with metal chelating abilities inspired from 
anthracyclines. While the exact mechanism of anthracycline-induced 
cytotoxicity is still unknown, the production of highly reactive free 
radicals and reactive oxygen species (ROS) is a generally accepted 
mechanism.[2, 6, 21] It arises from the presence of a quinone moiety that 
can be readily reduced by cellular reductants to yield a semiquinone 
radical.[21] In aerobic conditions, semiquinones can reduce molecular 
oxygen resulting in the formation of ROS, which can initiate radical 
chain reactions leading to oxidative stress and ultimately cellular 
death.[6] Given the importance of redox-active metal ions in the 
mechanism of toxicity of anthracyclines, it has been suggested that 
metal-chelating quinone moieties could considerably increase the rate of 
ROS generation, thus leading to higher cytotoxicity.[21, 22] 
Anthraquinone derivatives with chelating groups were shown to 





interesting candidates for cancer therapy, however, their cellular 
cytotoxicity has not been reported so far. 
Figure 1. A) Schematic representation of anthraquinone loaded peptide NPs 
and their disassembly in presence of reducing agent. B) Structure of the H3SSgT 
peptide. The hydrophilic tri-histidine (green) is linked to the hydrophobic [W-DL]3  
sequence (red) through a disulfide containing linker (blue). C) Structure of the 
anthraquinone derivatives Qc1, Qc2 and Qn. 
Using our MCMs, we entrapped three different anthraquinone 
derivatives as anticancer drug candidates (Qn, Qc1 and Qc2) (Figure 
1C), and evaluated the entrapment efficiency, morphology and size of 
the loaded NPs. Cytotoxicity of the compound with the highest loading 
efficiency, Qc2, was assessed on both HEK293T and HeLa cells. 
Finally, we confirmed the entrapment of Qc2 in the peptide NPs as 
well as release under reductive conditions using both cell lines. Our 
research aims at developing this stimuli-responsive NP-drug system 
into a possible alternative to currently used chemotherapies. 
Results and Discussion 
 
Nanoparticles Formation and Characterization 
 
The amphiphilic peptide H3SSgT self-assembles into MCMs, obtained 
from the aggregation of individual micelles (Figure 1A). These 
particles are formed by solvent exchange of ethanolic solutions to 
purified water (ddH2O), with multiple parameters such as the 
concentration of the peptide and the solvent exchange rate affecting 
their final size and morphology. In the case of the peptide H3SSgT, 
dialysis of a 0.2 mg mL-1 solution of the peptide in 50% ethanol against 
water allowed for the formation of particles of desired size and 
morphology. Imaging of the obtained NPs by transmission electron 
microscopy (TEM), revealed spherical structures (Figure 2 and S1) 
and dynamic light scattering (DLS) measurements showed that the 
NPs exhibited a mean hydrodynamic diameter (DH) between 200 and 
300 nm (Table 1 and S1). Transfer of the NP suspension into 3-(N- 
morpholino)propanesulfonic acid (MOPS, pH 6.5) buffer resulted in a 
shrinking of the particles without otherwise affecting their morphology, 
as observed by TEM (Figure S2) and DLS (Table S1). The observed 
shrinking  of  the  NPs  can  be  attributed  to  the  increased osmotic 
pressure resulting from the buffer. After their preparation in deionized 
water, the nanoparticles were transferred into MOPS buffer, which 
considerably increased the salt concentration and induced the 
mentioned osmotic pressure. Since this system is designed for 




Figure 2. A) Individual peptide NP s as observed by transmission (top) and 
scanning (bottom) electron microscopy. Scale bar = 100 nm. B) TEM micrograph 
of representative samples of Qc2-loaded peptide NPs and C) TEM micrograph 
of Qc2-loaded NPs after incubation (2h) with reducing agent TCEP. 
Payload Embedding and Characterization of Loaded 
Nanoparticles 
Entrapment of three different redox active anticancer drug candidates 
Qn, Qc1 and Qc2 (Figure 1C) was evaluated upon self-assembly of 
the peptide NPs. All three anthraquinone derivatives possess similar 
redox potentials, but differ with respect to their hydrophobicity, with 
Qc2 being the most hydrophobic due to its longer aliphatic side chain. 
Qc2 has an octyl side chain, Qc1 possesses only a butyl chain and Qn 
bares no side chain at all. As the peptide NPs are MCMs, they possess 
multiple hydrophobic inner cores and thus preferentially entrap 
hydrophobic compounds.[13, 14] Therefore, the structural differences 
between these anthraquinones can affect their loading efficiency 
within the hydrophobic cores of the peptide NPs. To prepare the 
loaded NPs, the anthraquinone was added to a peptide solution, 
diluted to a final concentration of 6 - 12 µM in 50% ethanol and 
dialyzed against water. The presence of the anthraquinones did not 
significantly affect the shape and size of the particles (Table 1, Figure 
S3). 
The concentration of anthraquinones in the NP suspension was 
quantified by reversed phase high-performance liquid 
chromatography (RP-HPLC) (Figures S7 and S8). The resulting 
concentrations were determined to be 2.8 ± 0.8 µM for Qn, 3.8 ± 0.7 
µM for Qc1 and 6.6 ± 0.6 µM for Qc2, in the NPs formed from initial 
concentrations of 0.2 mg mL-1 peptide and 12 µM of the 
anthraquinones (Table 1). In order to verify that the anthraquinones 
are indeed entrapped within the peptide NPs and not free in solution, 
a 12 µM solution of the free anthraquinone Qc2 was dialyzed following 
the same procedure as for NP formation. After dialysis, the detectable 
concentration was below 0.8 µM (< 6% initial concentration) (Figure 
S9), thus confirming efficient removal of the non-entrapped 
compounds. This confirms that, upon peptide NP formation, the 
anthraquinones are successfully entrapped within the particles and not 





The concentrations of entrapped anthraquinones Qc1 and Qn (2.8 ± 
0.8 µM and 3.8 ± 0.7 µM) are in line with the 3 µM previously reported 
for the hydrophobic model compound Bodipy[13] and correspond to 
loadings of 5 mg anthraquinone per gram of peptide (2.4 ± 0.4 mol%) 
for Qn and 8 mg g-1 (3.3 ± 0.6 mol%) for Qc1. In the case of Qc2, the 
loading efficiency was two times higher, reaching concentrations up to 
7 µM, corresponding to 15 mg Qc2 per gram of peptide (5.8 ± 0.5 
mol%) (Table 1 and S1). The higher entrapment efficiency of this 
compound, compared to Qc1, is due to the presence of a longer 
aliphatic chain (octyl for Qc2, butyl for Qc1), thus increasing its 
hydrophobicity. As a result, higher entropic driving forces are present 
between Qc2 and the hydrophobic cores of the NPs. The high loading 
efficiency for compound Qc2 supports its case as a candidate for 
cancer therapy and was selected for further evaluation. 
Table 1. Loading efficiency and sizes of peptide NPs loaded with the 
anthraquinone derivatives Qn, Qc1 and Qc2. 
minutes.[13] In the present case of anthraquinone entrapping NPs, the 
release profile could not be determined since the studied compounds 
lack fluorescent properties. However, TEM micrographs of 
anthraquinone loaded NPs incubated with 7 mM of the reducing agent 
tris(2-carboxyethyl)phosphine (TCEP) confirmed their disassembly 
(Figure 2C). TCEP was selected as the preferred reducing agent due 
to its high stability, high reactivity at pH 6.5 and irreversibility.[25,26] 
Given that the release occurs due to the triggered decomposition of 
the NPs in a reductive environment, similar release profiles can be 
expected for various hydrophobic compounds, including the 
anthraquinone Qc2. 
Cytotoxicity of Anthraquinones upon Release from Peptide 
Nanoparticles 
In order to compare the cytotoxicity of our filled NPs to the free 
anthraquinone, we first evaluated the cytotoxicity of the anthraquinone 
Pay- 
load 
Anthraquinone loading  Size in 
ddH2O 
Size in MOPS 
pH=6.5 
Qc2 alone using an MTS assay on two cell lines (HEK293T and HeLa). The 
cells were incubated in the presence of increasing concentrations 










(PDI)  including the control cells, was 1% and did not interfere with cell 
   viability. After 24 h, the viability of both HEK293T and HeLa cells in 
none 137 (0.30) N/A 
presence of free Qc2 was assessed and a cytotoxic effect was 
Qn 2.8 ± 
0.8 
 
Qc1 3.8 ± 
0.7 
 
Qc2* 6.6 ± 
0.6 
2.4 ± 0.4 5 ± 1 128 (0.36) N/A 
 
 
3.3 ± 0.6 8 ± 2 163 (0.25) N/A 
 
 
5.8 ± 0.5 15 ± 1 138 (0.25) 113 (0.26) 
observed at concentrations above 250 nM (Figure 3). 
 
 
ct: anthraquinone concentration after NP formation as determined by RP- 
HPLC, Rh: mean hydrodynamic radius obtained from DLS at 90°. * indicates 
concentrations after transfer in MOPS buffer. PDI – polydispersity index. 
N/A – not available 
These peptide nanoparticles possess high stability, as storage of Qc2 
loaded NPs in ddH2O at room temperature for up to 1 year did not 
significantly affect their size or morphology. For freshly prepared 
particles, the hydrodynamic radius was measured to be 159 nm (PDI 
of 0.27) and 173 nm (PDI of 0.34) after one year of storage, with TEM 
micrographs confirming that the spherical structure was retained 
(Figure S6). The very slight increase in mean hydrodynamic radius 
and PDI is due to the presence of few aggregates of smaller NPs, as 
visible in Figure S6. Similarly to the non-loaded particles, a decrease 
in average hydrodynamic radius from 138 nm (PDI of 0.25) to 113 nm 
(PDI of 0.26) was observed after transferring Qc2 loaded particles into 
MOPS buffer (Table 1, Figure S4 and S5). This decrease in size 
results in particles more suitable for extended circulation times and 
accumulation in tumor tissue via the EPR effect.[17] 
The presence of a disulfide bond in the backbone of the amphiphilic 
peptide H3SSgT is intended to trigger the destruction of the NPs in 
reductive environments and induce the release of the anthraquinones. 
The release profile of the hydrophobic model payload Bodipy upon 
incubation in 10 mM dithiothreitol (DTT) was previously reported and 






























Figure 3. Viability of A) HEK293T and B) HeLa cells after exposure to the 
anthraquinone Qc2 (black), an equivalent concentration of Qc2 entrapped in 
peptide NPs with (blue) and without (green) pre-treatment with the reducing 
agent TCEP. The bar graphs represent the mean viability ± SD (multiple t - test, 





For HEK293T cells, the EC50 of Qc2 was estimated to be in the range 
of 500 nM (Figure S10), whereas for HeLa cells it was higher (around 
900 nM) (Figure S11). With respect to the HeLa cells, the EC50 is 
comparable to values reported for DOX.[13] Due to the higher loading 
efficiency of Qc2 as compared to DOX, the amount of peptide 
necessary to reach a similar toxicological effect is much lower for Qc2 
(around 8-fold), which is a significant advantage of this drug/NP 
combination. 
Having determined the concentration range where Qc2 elicits a toxic 
effect on both cell lines, we proceeded to investigate the behavior of 
the Qc2-loaded nanoparticles in the presence and absence of a 
reducing agent. In absence of a reducing agent, peptide NPs loaded 
with Qc2 showed no effect on either cell line (Figure 3). This confirms 
not only the previously reported absence of cytotoxicity for these NPs, 
but also efficient shielding of the tested anthraquinone through 
entrapment within the NPs. These results also indicate that the 
anthraquinone Qc2 does not leach out and is retained within the 
peptide NPs. For a DDS to be effective, a target-selective trigger must 
release the entrapped drug, preferentially. Here, once the NPs are 
exposed   to  a  reductive   environment,  such  as   that  surrounding 
tumors,[27] the disulfide bond of H3SSgT breaks and the NPs are 
destroyed, leading to drug release. To confirm that the NPs can 
efficiently release their payload in reductive environments, we 
incubated the cells in presence of NPs pre-treated with 7 mM of the 
reducing agent TCEP. We observed a significant decrease in cell 
viability, for both cell lines, in the presence of the pre-treated NPs, 
reaching levels comparable to those of the free anthraquinone (Figure 
3, S10 and S11). This proves that the NPs release the active 
anthraquinone Qc2 in a reductive environment. TCEP was used to 
ensure the full disassembly of the NPs and to study the release of 
Qc2; however, it would be interesting to further study the release of 
Qc2 in a 3D cell culture where the tumor microenvironment can be 
accurately modeled and the use of external reducing agents would 
not be necessary.[28, 29] In addition, the MCM structure of the NPs is 
expected to hinder the accessibility of the disulfide bonds to enzymes 
present in biological fluids, thus limiting their enzymatic degradation. 
Preliminary results suggest that 24h incubation in fetal calf serum 
does not significantly affect the morphology of the NPs (Figure S12). 
Conclusions 
 
Three different anticancer drug candidates, based on redox active 
anthraquinones, were entrapped within peptide-based NPs of 
approximately 200 nm. The NPs were formed by self-assembly of a 
reduction responsive amphiphilic peptide. One compound, Qc2, 
previously shown to produce ROS at a higher rate than DOX, was 
loaded within NPs with a high entrapment efficiency, reaching up to 15 
mg per g peptide (5.8 mol%). This is more than 8 times higher than 
the loading efficiency previously reported for DOX. The compound 
Qc2 exhibited significant toxicity towrds both HEK293T and HeLa 
cells, whereas NPs loaded with Qc2 showed no cytotoxicity, at 
comparable anthraquinone concentrations. Pre-treatment of Qc2 
loaded NPs with reducing agent resulted in release of Qc2 and an 
increase in cytotoxicity to levels comparable to the free compound. 
The efficient loading of biocompatible peptide based NPs with 
hydrophobic anthraquinones, combined with the stimuli-responsive 
release of the payload, confirms the potential of this anthraquinone- 
peptide system as a drug delivery vehicle for anti-cancer drug 
candidates. Indeed, a NP based delivery system capable of targeting 
tumor sites through the EPR effect and capable of releasing highly 
toxic molecules selectively, should allow for efficient treatment while 
minimizing the side effects caused by non-selective drugs. While this 
system shows promising results, further characterization in vivo is 





The  peptide  H3SSgT  with  sequence  H2N- H3-X-[W-DL]3-W-CONH2, 
(with   X  =   –(CH2)2-S-S-(CH2)2-NH-CO-(CH2)2-CO– and DL = D- 
Leucine) was synthesized, purified and characterized as previously  
described.[1] The anthraquinones Qc1 (2-phenyl-4-(butylamino)naphtho[2,3- 
h]quinoline-7,12-dione), Qc2 (2-phenyl-4-(octylamino)naphtho[2,3- h]quinoline-
7,12-dione) and Qn (2-phenyl-5-nitronaphtho[2,3-g]indole- 6,11-dione) were 
synthesized and purified as described previously.[23] 
General Methods 
 
Methods on peptide nanoparticles formation, characterization and 
anthraquinone quantification can be found in the SI. 
Payload Embedding in Peptide Nanoparticles 
 
The anthraquinones were dissolved in ethanol to a concentration of 
100 µM and stored in the dark. Typically, solutions with final 
concentrations of 0.2 mg mL-1 peptide and 12 µM anthraquinone were 
prepared in 50% ethanol and dialyzed as described in the SI. The final 
anthraquinone concentration was determined by RP-HPLC 
Anthraquinone Quantification 
 
Anthraquinone concentration was determined by RP-HPLC 
(Prominence 20A, Shimadzu, Japan) using a C18 reverse phase 
column (Merck Chromolith RP-18e, 100x4.6 mm, Merck, Germany) 
and a gradient from 0-100% acetonitrile/water (0.1% TFA) over 10 
minutes. Injection volumes were 30 µL and the chromatograms were 
recorded at 280 nm. Concentrations were calculated using a 
calibration curve obtained by reporting the area under the peak as a 
function of the anthraquinone concentration. The calibration samples 
were prepared in triplicate by dilution of a stock solution of the 
anthraquinone in ethanol. Peptide containing samples were dissolved 
in 1:1 with dimethylformamide and vortexed for 30 s prior to injection. 
Cell Culture 
 
HEK293T and HeLa cells were cultured in Dulbecco’s Modified Eagle 
Medium with GlutaMAXTM-I and supplemented with 10% Fetal calf 





and 100 µg mL-1 Streptomycin). Cells were kept in a humidified 
atmosphere with 5% CO2 at 37
oC. 
Cell Viability Assay 
 
To determine cell viability, the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (MTS) was used according to the 
manufacturer’s protocol. Cells were seeded at a density of 5 000 
cells/well in a 96-well plate and cultured for 24 h. After 24 h, free Qc2 
in ethanol, NPs containing Qc2 in MOPS buffer, or NPs containing 
Qc2 pre-incubated (4h at 37°C) with 7mM TCEP in MOPS buffer were 
added to the cells to reach final concentrations of Qc2 ranging from 0 
to 1 mM. Concentrations of ethanol or TCEP were normalized for all 
tested Qc2 concentrations to 1 vol% and 1 mM respectively. Cells 
were further incubated in presence of compounds for 24 h after which 
20 µL MTS reagent was added to each well. After 2 h absorbance was 
measured at 490 nm using a Spectramax plate reader (Molecular 
Devices LLC, USA). Background absorbance, measured in control 
wells containing all assay components except cells, was subtracted 
from each well and normalized to control cells containing all 
components except Qc2 or Qc2 loaded NPs. The normalized data was 
plotted using Prism7 (GraphPad Software) and statistics were 
performed using the built-in multiple t-test function (P<0.01 was 
considered significant, n = 4). 
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